Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1/2 4Phase 3 2Phase NA 1Phase 1 1

Status

Withdrawn 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 1Fallopian Tube Neoplasms 1

Interventions

Blood Specimen Collection 35Methods 25Early Intervention, Educational 24Standard of Care 21Colposcopy 21Surveys and Questionnaires 19Educational Status 18Sentinel Lymph Node Biopsy 17Cisplatin 17Counseling 16Brachytherapy 16Exercise 15Interviews as Topic 13Carboplatin 13Therapeutics 12Surgical Procedures, Operative 11Paclitaxel 11Magnetic Resonance Spectroscopy 11Indocyanine Green 11Biopsy 11Radiotherapy 10Practice Guidelines as Topic 10Palliative Care 10Human Papillomavirus DNA Tests 10Behavior Therapy 10Specimen Handling 9Radiotherapy, Intensity-Modulated 9Psychiatric Rehabilitation 9Lymph Node Excision 9Genetic Testing 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × oregovomab × Gynecologic × Clear all
NCT00551265 2017-07-14

Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Responded to Second-Line Chemotherapy

GOG Foundation

Phase NA Withdrawn
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡